We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

286 hedge funds and large institutions have $2.55B invested in Amicus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 115 increasing their positions, 88 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 88

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

0% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 40

0.43% less ownership

Funds ownership: 102.2%101.76% (-0.43%)

1% less funds holding

Funds holding: 290286 (-4)

11% less capital invested

Capital invested by funds: $2.88B → $2.55B (-$324M)

36% less call options, than puts

Call options by funds: $3.21M | Put options by funds: $5.04M

Holders
286
Holders Change
-4
Holders Change %
-1.38%
% of All Funds
3.83%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
40
Increased
115
Reduced
88
Closed
40
Calls
$3.21M
Puts
$5.04M
Net Calls
-$1.84M
Net Calls Change
-$1.73M
Name Holding Trade Value Shares
Change
Change in
Stake
AW
326
Avion Wealth
Texas
+$490 +53 New

FOLD Hedge Fund Activity: Q1 2025 in Review

286 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2025, worth a combined $2.55B — down 11% from $2.88B a quarter earlier.

Fund positioning in FOLD was balanced in Q1 2025: 40 funds opened new positions, 40 closed out, 115 added to existing stakes and 88 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $27.6M. The largest seller was Fiera Capital (Canada), exiting entirely with an estimated $28.6M sold.

  • 286 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2025, down from 290 in Q4 2024.
  • Funds reported $2.55B of Amicus Therapeutics stock for Q1 2025, down 11% quarter-over-quarter.
  • 40 funds opened new Amicus Therapeutics positions in Q1 2025 and 40 closed out, a net change of 0 holders.
  • The largest Amicus Therapeutics buyer in Q1 2025 was Point72 Asset Management, an estimated $27.6M added.
  • The largest Amicus Therapeutics seller in Q1 2025 was Fiera Capital (Canada), an estimated $28.6M sold.

Based on aggregated 13F filings for Q1 2025.